Axonics Modulation Technologies (NASDAQ:AXNX) and Hill-Rom (NYSE:HRC) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, dividends, profitability and risk.
Hill-Rom pays an annual dividend of $0.84 per share and has a dividend yield of 0.9%. Axonics Modulation Technologies does not pay a dividend. Hill-Rom pays out 17.7% of its earnings in the form of a dividend. Hill-Rom has raised its dividend for 8 consecutive years.
This is a breakdown of recent recommendations and price targets for Axonics Modulation Technologies and Hill-Rom, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Axonics Modulation Technologies||0||0||4||0||3.00|
Axonics Modulation Technologies presently has a consensus price target of $23.23, indicating a potential downside of 25.02%. Hill-Rom has a consensus price target of $108.71, indicating a potential upside of 13.26%. Given Hill-Rom’s higher probable upside, analysts clearly believe Hill-Rom is more favorable than Axonics Modulation Technologies.
Valuation & Earnings
This table compares Axonics Modulation Technologies and Hill-Rom’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Axonics Modulation Technologies||$710,000.00||1,233.35||-$32.48 million||($4.64)||-6.68|
|Hill-Rom||$2.47 billion||2.60||$252.40 million||$4.75||20.21|
Hill-Rom has higher revenue and earnings than Axonics Modulation Technologies. Axonics Modulation Technologies is trading at a lower price-to-earnings ratio than Hill-Rom, indicating that it is currently the more affordable of the two stocks.
This table compares Axonics Modulation Technologies and Hill-Rom’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Axonics Modulation Technologies||N/A||N/A||N/A|
Insider and Institutional Ownership
31.4% of Axonics Modulation Technologies shares are owned by institutional investors. Comparatively, 84.8% of Hill-Rom shares are owned by institutional investors. 0.7% of Hill-Rom shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Hill-Rom beats Axonics Modulation Technologies on 13 of the 16 factors compared between the two stocks.
Axonics Modulation Technologies Company Profile
Axonics Modulation Technologies, Inc., a medical technology company, focuses on the design, development, and commercialization of sacral neuromodulation solutions (SNM) solutions. The SNM therapy is primarily used to treat patients with overactive bladder, including urinary urgency incontinence and urinary urgency frequency, fecal incontinence, and urinary retention. Its proprietary r-SNM System delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of urinary and fecal dysfunction. The company was formerly known as American Restorative Medicine, Inc. and changed its name to Axonics Modulation Technologies, Inc. in August 2013. Axonics Modulation Technologies, Inc. was founded in 2012 and is based in Irvine, California.
Hill-Rom Company Profile
Hill-Rom Holdings, Inc. operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment. It also provides patient monitoring and diagnostics products, such as blood pressure, physical assessment, vital signs monitoring, diagnostic cardiopulmonary, diabetic retinopathy screening, and thermometry products; and respiratory health products comprising Vest System, VitalCough System, MetaNeb System, and Monarch systems to assist patients in the mobilization of retained blockages. In addition, the company offers surgical solutions that include surgical tables, lights, and pendants; positioning devices for use in shoulder, hip, spinal, and lithotomy surgeries, as well as platform-neutral positioning accessories for operating room tables; and operating room surgical safety and accessory products, which comprise scalpels and blades, light handle systems, skin markers, and other disposable products. Further, it is involved in the sales and rental of products to acute and extended care facilities through direct sales force and distributors; sales and rental of products directly to patients in the home; and sales to primary care facilities through distributors. Additionally, the company offers continuum of clinical care, including acute care and primary care, as well as clinical research organizations. Hill-Rom Holdings, Inc. was founded in 1969 and is headquartered in Chicago, Illinois.
Receive News & Ratings for Axonics Modulation Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axonics Modulation Technologies and related companies with MarketBeat.com's FREE daily email newsletter.